Efficacy and toxicity of capecitabine combined with intensity-modulated radiotherapy after D1/D2 lymph node dissection in patients with gastric cancer

Table 1 Clinical target volume for elective nodal regions according to the Japanese Gastric Cancer Association guidelines

Tumor location	CTV for elective nodal regions
Upper 1/3rd or gastroesophageal junction	110, 1-3, 7, 9-11
Middle 1/3rd	1-3, 5-13, 141, 16a
Lower 1/3rd	3, 5-9, 11p, 12-13, 141, 16a

¹No. 14 was included in the clinical target volume (CTV) only when the surface or parenchyma of the pancreas was involved by the tumor. 110: Paraesophageal lymph nodes (LNs) in the lower thorax; 1: Right paracardial LNs; 2: Left paracardial LNs; 3: LNs along the lesser curvature; 5: Suprapyloric LNs; 6: Infrapyloric LNs; 7: LNs along the left gastric artery; 8: LNs along the common hepatic artery; 9: LNs around the celiac artery; 10: LNs at the splenic hilum; 11: LNs along the splenic artery (11p: LNs along the proximal splenic artery); 12: LNs in the hepatoduodenal ligament; 13: LNs on the posterior surface of the pancreatic head; 14: LNs along the root of the mesentery; 16a: LNs around the abdominal aorta (above the level of the inferior border of the left renal vein). CTV: Clinical target volume.